Introduction
============

Osteosarcoma (OS) is the most common primary malignant bone cancer, which mainly affects children, adolescents, and young adults.[@b1-cmar-10-4959] Due to the lack of specific presentation and high aggressiveness, almost 20% of OS patients show clinically detectable metastases at presentation, and most metastases occur in the lung. Currently, for early-stage disease without metastases, treatment strategies mainly include standard chemotherapy administered before and after surgery followed by radiation, with a 5-year survival rate of 60%--70% for OS patients.[@b2-cmar-10-4959] However, prognosis of OS patients with locally advanced or distant metastasis when diagnosed or in recurrent disease is still poor, and a previous study demonstrated that the median survival time for these late-stage patients was only 23 months.[@b3-cmar-10-4959] Although the response to treatment in a subset of OS patients was improved due to the development of chemotherapy and targeted therapy, overall survivals were not significantly prolonged.[@b2-cmar-10-4959],[@b4-cmar-10-4959] Therefore, there is an urgent need for comprehensive understanding of the underlying factor of OS biology, which could assist in the identification of more effective molecular biomarkers for diagnosis, prognosis, and development of a more effective treatment strategy and therapeutic target to improve patient survival.

The precise etiology of OS remains partially unknown. However, as a multifactorial disease, several factors have been identified in OS development, including environmental and genetic factors.[@b5-cmar-10-4959] Genetic factors might play a key role in OS pathogenesis. To date, several previous studies have reported associations of DNA repair gene variants in biologically plausible pathways with OS risk,[@b6-cmar-10-4959]--[@b10-cmar-10-4959] such as *ERCC1*, *ERCC2*, *APE, and so on*. X-ray repair cross-complementing group 1 (*XRCC1*) is a member of the DNA repair gene family, which is responsible for fixing DNA base damage and single-strand breaks through interacting with DNA components at the damage site.[@b11-cmar-10-4959],[@b12-cmar-10-4959] XRCC1 polymorphisms have been linked to cancer development in several types of cancer.[@b13-cmar-10-4959]--[@b20-cmar-10-4959] However, the association of XRCC1 polymorphism with OS still was not fully clear. Therefore, we conducted the present study to determine the association between rs25487, rs1799782, rs25489, and rs3213245 polymorphisms and OS in a cohort of Chinese Han population.

Materials and methods
=====================

Study subjects
--------------

In this case--control study, a total of 146 patients with primary OS were enrolled to the Department of Orthopedics of Shandong Qianfoshan Hospital (Jinan, China) between January 2013 and December 2015. All subjects had to meet the following criteria: Chinese Han descent; newly diagnosed, previously untreated, histologically confirmed primary OS; and no history of other cancers. Two hundred and forty-eight age- and gender-matched controls without orthopedic disease or cancer were included. Prior to treatment, peripheral blood samples were collected from each recruited subject for DNA extraction. Demographic and clinicopathologic features of all OS patients were obtained from the medical records, including age, gender, tumor location, tumor size, tumor grade, tumor metastasis, and response to chemotherapy. One hundred and fourteen of 146 OS patients were involved in follow-up analysis. Overall survival was defined as the time from surgery to the date of OS-related death or last follow-up. This study was approved by the Institutional Review Board of Shandong Qianfoshan Hospital. Written informed consent was obtained from all participants. We confirmed that all methods were performed in according with the relevant guidelines and regulation. All identifying information of patient had been removed from all text/figures/tables.

Single-nucleotide polymorphisms (SNP) genotyping analysis
---------------------------------------------------------

Genomic DNA from peripheral lymphocytes was obtained using a QIAamp DNA Blood Mini kit (Qiagen NV, Venlo, the Netherlands) based on the manufacturer's instructions. Genotyping analysis was performed using custom TaqMan SNP genotyping assays with TaqMan genotyping master mix (Thermo Fisher, CA, USA) and an ABI Prism 7900HT genetic detection system. The final reactive system is 25 µL, including 12.50 µL of master mix, 1.25 µL of assay mix, and 11.25 µL of ddH2O. Reactive conditions of TaqMan SNP Genotyping assay were as follows: 95°C for 15 seconds and 60°C for 1 minute, repeated for 40 cycles. Eventually, the frequencies of genotype or allele of XRCC1 polymorphisms were determined based on the allelic discrimination plots. To ensure the accuracy of the results, 10% of samples were randomly chosen for repeated assays, and no inconsistent results were found.

Plasmid constructs
------------------

According to the previously described methods, we constructed a luciferase reporter plasmid using the pGL3-Basic reporter vector (Promega, Madison, WI, USA).[@b15-cmar-10-4959] A fragment (from −818 to −22) in the XRCC1 promoter region from the subjects homozygous for rs3213245 T or C allele was amplified using the following primers: 5′-AAACGCGTTT-GCGTAGAATCCAGGTTCC-3′ and 5′-AAAGATCTTGGC-CAGAAGGATGAGGTAG-3′. Both the amplified fragments and pGL3-basic vector were digested with Mlu I (A\^CGCGT/TGCGC\^A) and Bgl II (A\^GATCT/TCTAG\^A) enzymes (New England BioLabs Inc., Ipswich, MA, USA), and the amplified fragments were cloned into pGL3-basic vector. Subsequently, the vectors were sequenced to validate the orientation and integrity of plasmid construct.

Human OS cell culture and luciferase assay
------------------------------------------

SaOS-2 and MG-63 cells (purchased from Institute of Cellular Research, Chinese Academy of Science, Shanghai, China) were cultured in RPMI 1640 containing fetal bovine serum (10%; HyClone, Logan, UT, USA), penicillin (100 units/mL; Gibco; Thermo Fisher Scientific, Waltham, MA, USA), and streptomycin (100 µg/mL; Gibco). SaOS-2 and MG-63 cells were seeded in 24-well plates before transfection. pGL3 luciferase reporters containing rs3213245 T or C allele were transfected into cells with the PolyJet DNA In Vitro Transfection Reagent (Signagen Laboratories, MD, USA). After 24 hours of incubation, cells were lysed in passive lysis buffer. Firely and Renilla luciferase signals were measured with a dual-luciferase reporter assay system and a microplate reader. The negative control is the pGL3-basic vector without an insert, while Renilla plasmid (pRL-SV40) was used as an internal control. Luciferase assay was carried out using the Dual Glo Luciferase System (Promega, CA, USA) according to the manufacture's instruction. To ensure the accuracy of experiments, independent triplicate wells were done.

RNA isolation and quantitative real-time PCR (qRT-PCR)
------------------------------------------------------

Total RNA was obtained from tumor tissue. Approximately 1 µg of total RNA was used for cDNA synthesis by a reverse transcription kit and qRT-PCR was performed after isolating cDNA. XRCC1 mRNA expression was determined relative to GAPDH using the equation 2− ΔΔCt(ΔCt = Ct~XRCC1~ − Ct~GAPDH~. The primers were as follows: 5′-AAGCAACCCCAGACCAAAAC-3′ (forward) and 5′-CCCCATTGTCCTGTCCTTCT-3′ (reverse) for XRCC1, and 5′-CCAGAACATCATCCCTGCCT-3′ (forward) and 5′-CCTGCTTCACCACCTTCTTG-3′ (reverse) for GAPDH.

Protein isolation and Western blotting
--------------------------------------

The 146 OS patients were divided into three groups based on the distribution of rs3213245 genotype. To assess the effect of rs3213245 polymorphism on XRCC1 protein expression, we randomly selected 12 OS tumor tissues and isolated the protein according to the previously described method.[@b10-cmar-10-4959] Subsequently, Western blotting was performed to evaluate the XRCC1 protein expression. Thirty microgram of extracted protein was subjected to 10% SDS-PAGE and transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA). Membranes were blocked with 5% nonfat milk in TBST buffer (containing 0.1% Tween-20) and then incubated with human XRCC1 antibody (1:1,000 dilution, ab1838, Mouse IgG; Abcam, Cambridge, UK) and GAPDH antibody (1:1,000 dilution, sc-32233; Mouse IgG; Santa Cruz Biotechnology Inc., Dallas, TX, USA) at 4°C overnight. Horseradish peroxidase (HRP)-conjugated antirabbit IgG and antimouse IgG were used as the secondary antibody (1:5,000 dilution, Beoytime Biotech, Shanghai, China). Signals were captured using an HRP chemiluminescent kit (Beoytime Biotech).

Statistical analysis
--------------------

The association between XRCC1 genotypes and OS risk was assessed with ORs using an unconditional logistic regression model. Deviations from Hardy--Weinberg equilibrium were assessed with a chi-squared test. Survival probabilities were determined with a Kaplan--Meier curve, and significant differences were analyzed with a logrank test. Cox proportional hazards models were used to analyze the associations between genotypes and OS survival. HR and 95% CIs were estimated using multivariable models. XRCC1 expression among patients with different genotypes were compared with a Student's *t*-test. All statistical analyses were performed with SPSS 22.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA). *P*\<0.05 was considered statistically significant.

Results
=======

Association of XRCC1 polymorphisms with OS risk
-----------------------------------------------

The clinical characteristics of OS patients and normal controls were present in [Table 1](#t1-cmar-10-4959){ref-type="table"}. No significant difference in age and gender could be observed. All the genotype frequencies of rs25487, rs1799782, rs25489, and rs3213245 did not deviate from Hardy--Weinberg equilibrium in control groups (all *P*\>0.10). Significant differences between OS patients and controls could be only observed in rs3213245 ([Table 2](#t2-cmar-10-4959){ref-type="table"}). Under the additive model, significantly increased risk of OS could be observed in subjects with TC genotype when compared with TT genotype at rs3213245 (OR =1.74, 95% CI 1.07--2.84). Individuals with the minor C allele (TC+ CC) showed a significant increase in the risk of OS development (OR =1.83, 95% CI 1.14--3.00). Similarly, individuals carrying the C allele had significantly increased risk of developing OS compared with T allele (OR =1.79, 95% CI 1.16--2.76). For rs25487, patients with the minor A allele seem to have a lower risk of OS development compared with G allele (OR =0.78, 95% CI 0.57--1.08), but without significant difference. Under dominant, recessive, and additive models, a decreased risk of OS development could be observed in subjects carrying the A allele, but the difference did not reach statistical significance (all *P*\>0.05). In addition, the distribution and frequency of rs1799782 and rs25489 were similar between OS patients and normal controls. Furthermore, Haploview analysis did not reveal an LD among these four XRCC1 polymorphism in our cohort. Therefore, the association of the XRCC1 haplotype with OS risk was not further evaluated.

rs3213245 and clinicopathologic characteristics
-----------------------------------------------

The results of stratification analysis by clinicopathologic characteristics were described in [Table 3](#t3-cmar-10-4959){ref-type="table"}. OS patients carrying TC genotype at rs3213245 were more likely to be with larger tumor size (OR =2.21, 95% CI 1.04--4.72) and metastasis (OR =2.55, 95% CI 1.18--5.51). Patients carrying C allele at rs3213245 were more susceptible to be with metastases at diagnosis (OR =2.86, 95% CI 1.50--5.43). For response to chemotherapy, OS patients carrying TC genotype or C allele tended to have a good response to chemotherapy, but without significant difference (*P*=0.09, *P*=0.35). In addition, we could observe that all three OS patients with CC genotype were in the femur/tibia/fibula, had metastases, and showed good response to chemotherapy. Besides, no other significant relationship could be observed.

rs3213245 and prognosis
-----------------------

Kaplan--Meier curves were plotted to determine the association of survival rate with rs3213245. Significant difference in survival rate was detected among patients with different genotypes at rs3213245 ([Figure 1](#f1-cmar-10-4959){ref-type="fig"}). The results revealed that OS patients carrying TC + CC genotype at rs3213245 had shorter survival time than those with TT genotype alone ([Figure 1](#f1-cmar-10-4959){ref-type="fig"}, *P*=0.04). The multivariate analysis of survival time using the Cox proportional hazards model revealed that distant metastases and response to chemotherapy were two independent prognostic factors for worse survival in OS patients (HR =4.01, 95% CI 2.34--6.09; HR =2.32, 95% CI 1.67--4.57; [Table 4](#t4-cmar-10-4959){ref-type="table"}). However, rs3213245 was not independently associated with overall survival (HR =1.41, 95% CI 0.86--2.62).

rs3213245 and XRCC1 transcriptional activity, XRCC1 expression
--------------------------------------------------------------

Compared with T allele, the constructed luciferase reporter vectors with C allele could yield a 60% decrease in the relative luciferase activities in SaOS-2 and MG-63 cells ([Figure 2](#f2-cmar-10-4959){ref-type="fig"}). We further evaluate the expression levels of XRCC1 in OS patients to determine the relationship between rs3213245 polymorphism and XRCC1 expression. Similar to transcriptional activity, XRCC1 mRNA levels were significantly decreased in OS patients carrying the C allele ([Figure 3A](#f3-cmar-10-4959){ref-type="fig"}, *P*\<0.01). The differences between CC and TC genotypes were not statistically significant due to a smaller sample size. In addition, XRCC1 protein expression levels of patients carrying TC or CC genotype were lower than those with TT genotype ([Figure 3B](#f3-cmar-10-4959){ref-type="fig"}). Taken together, the observation of lower XRCC1 expression in OS patients carrying TC or CC genotype suggested that C allele at rs3213245 is a genetic risk factor for OS.

Discussion
==========

XRCC1 is involved in base excision repair (BER) of DNA and has variant genotypes associated with modified DNA repair function. In XRCC1 knockout mice, spontaneous chromosome aberrations and embryonic lethality supported the importance of XRCC1 in genome maintenance.[@b21-cmar-10-4959] In the present study, we assessed the association of four common XRCC1 gene polymorphisms with OS, and observed that C allele at rs3213245 was associated with increased risk of OS development, larger tumor size as well as metastases compared with T allele and the homozygous TT genotype. Survival analysis showed that patients carrying C allele at rs3213245 had worse survival. In addition, the present study also found that the T to C substitution at rs3213245 could decrease the transcription activity of XRCC1 gene in vitro. Furthermore, XRCC1 mRNA and protein expression were downregulated in vivo in OS patients carrying the C allele, suggesting that rs3213245 is indeed a functional polymorphism both in vitro and in vivo as well as being a genetic biomarker for the risk and prognosis of OS.

DNA repair systems play a vital role in protecting against tumorigenesis, and genetic defects in DNA repair systems could cause tumors.[@b22-cmar-10-4959] Accumulated evidence revealed that the polymorphisms located in the coding region could reduce the DNA repair capacity, and the genetic polymorphism in the regulatory region could decrease the expression of DNA repair genes, which were linked to the risk of tumor development, such as APE1, BRCA1, XPF, and ERCC1.[@b10-cmar-10-4959],[@b23-cmar-10-4959]--[@b26-cmar-10-4959] The BER pathway is one important mechanism of all DNA repair pathways, which could repair DNA base damage and single-strand breaks. As a scaffold protein in BER, XRCC1 assembles a DNA protein complex at the damaged site, while interacting with most of the core components that participate in the BER pathway to accomplish DNA repair process.[@b27-cmar-10-4959] The *XRCC1* gene located on chromosome 19q13.2 consists of 17 exons, and there are several gene polymorphisms within *XRCC1* gene.[@b28-cmar-10-4959]

The most widely studied SNPs were rs1799782, rs25487, and rs25489. rs1799782 polymorphism is located in exon 6 of XRCC1 and is a C\>T substitution in codon 194, which could cause an Arg194Trp variant. Although rs1799782 polymorphism has been extensively studied, contradictory results on its functional significance have been reported. Some previous studies have described a lower DNA repair efficiency associated with the 194Trp variant of XRCC1 protein,[@b29-cmar-10-4959],[@b30-cmar-10-4959] while others have reported a decreased DNA repair in 194Arg variant.[@b31-cmar-10-4959]--[@b33-cmar-10-4959] Also, some investigators have not found any association between rs1799782 and defective DNA repair.[@b34-cmar-10-4959],[@b35-cmar-10-4959] The association of rs1799782 with cancer risk remains controversial. Some previous studies have reported a significant association of rs1799782 with thyroid cancer,[@b16-cmar-10-4959] colorectal cancer,[@b19-cmar-10-4959] lung cancer,[@b17-cmar-10-4959] and cervical cancer,[@b18-cmar-10-4959] while no significant association could be observed with breast cancer,[@b36-cmar-10-4959] pancreatic cancer,[@b37-cmar-10-4959] and gastric cancer.[@b15-cmar-10-4959] rs25487 and rs25489 polymorphisms are another widely studied polymorphism with evidences supporting a quantitative effect of the genotype on the phenotype.[@b36-cmar-10-4959] The homozygous variant (Gln/Gln) at rs25487 has been shown to have three to fourfold lower capacity to remove DNA adducts or oxidized DNA damage. Similar to rs1799782, rs25489 also was shown to have the ability of diminishing the repair function but additional quantitative information was uncertain. The association of rs25487 and rs25489 with cancer risk has also remained inconsistent. Several previous studies reported a positive association, while some did not observe the different distribution of these two polymorphisms between cancer patients and normal controls.[@b15-cmar-10-4959],[@b36-cmar-10-4959] As for OS, Wang and Wu have reported that rs25487 polymorphism was significantly associated with the development of OS rather than rs25489.[@b38-cmar-10-4959] In the present study, we did not find any significant association between those three polymorphism and OS risk. The possibilities for this discrepancy were different tumor types and different ethnicities.

rs3213245 (--77T\>C) is a novel polymorphism located in the promoter-binding sequence. Previous studies have demonstrated that this polymorphism could decrease XRCC1 levels by modifying gene expression.[@b14-cmar-10-4959],[@b15-cmar-10-4959] In Chinese population, some investigations have demonstrated that this polymorphism was associated with a higher risk of lung cancer and gastric cancer. Consistent with those results, we also found a positive relationship between rs3213245 and increased risk of OS. Meanwhile, our results also showed that patients who carried rs3213245 mutation genotype had worse survival. On the basis of the luciferase experiment, this polymorphism could decrease the transcriptional activity of *XRCC1* gene. Combined with the phenomenon that OS patients with C allele had low expression of XRCC1 in OS tumor tissues, these results suggested that rs3213245 polymorphism could be involved in the decreased level of XRCC1 in OS tumor tissue. The accurate mechanism underlying the association of rs3213245 with OS remained unclear, but we speculated this polymorphism may affect susceptibility to OS through the influence of rs3213245 on XRCC1 expression. Previous study also revealed that rs25487 GG genotype could decrease the function of XRCC1, and those with rs25487 GG genotype showed significantly better ORR; thus, this genotype could act as predictive factors in NSCLC patients treated with platinum-based chemotherapy.[@b39-cmar-10-4959] Therefore, in our paper, we observed that patients with rs3213245 minor C allele tended to have good response to chemotherapy, although there are no significant differences.

Based on genotype effect on phenotype and allele frequency, rs25487 and rs3213245 polymorphism have the largest potential to affect the function of XRCC1, eventually influencing the toxicodynamic response to environmental factors and contributing to the initiation of cancer. Consistent with this theory, our result found a relatively big difference in the frequency and distribution of both rs25487 and rs3213245, although there was no statistical significance in rs25487. In addition, both Hao's and Liu's studies found that rs1799782, rs25487, rs25489, and rs3213245 were in linkage disequilibrium, but we did not observe that rs1799782, rs25487, rs25489, and rs3213245 were in linkage disequilibrium in our study population.[@b14-cmar-10-4959],[@b15-cmar-10-4959] Both studies were performed in the Chinese population, and the frequency of XRCC1 polymorphisms was similar in normal controls among these studies. Therefore, we speculated that one possibility for this discrepancy is the sample size. Hao's and Liu's studies included 2,140 subjects and 1,999 subjects, respectively, but our study only included 146 OS patients and 248 healthy controls. Therefore, whether four SNPs were in linkage disequilibrium, as well as the association of the haplotype of these four SNPs with OS risk, requires future exploration. In addition, the discrepancy in the genetic polymorphism may be attributed to different ethnicities/races. In our study, we only included the Chinese population. The role of these polymorphisms in other ethnic populations should be explored in future research.

Of note, there were several limitations in the present study. First, the sample size was relatively small. In particular, the specific role of rs3213245 and rs25489 in OS development requires further confirmation in a large cohort study because of the low frequency of mutation. Second, although we found that rs3213245 could affect the transcriptional activity, mRNA and protein expression of XRCC1, the specific mechanism was not clear. Whether this polymorphism could affect the binding affinity of the transcription factor or miRNA also need to be validated in the future. Third, reports on the association of XRCC1 polymorphism with OS were relatively scarce, and we only conducted this study in the Chinese Han population, so the frequency of XRCC1 polymorphisms in other ethnic groups required to be confirmed.

Conclusion
==========

The present study aimed to determine the association of the XRCC1 polymorphism with OS. The results showed that rs3213245 was associated with the increased risk of OS development. The C allele at rs3213245 could reflect a worse prognosis of the OS patients. In addition, the C allele at rs3213245 could affect XRCC1 production in vitro and in vivo in OS patients.
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![Kaplan--Meier survival curves.\
**Notes:** Kaplan--Meier survival curves of OS patients with different rs3213245 genotypes (28 events for TC + CC, 35 events for TT), XRCC1 rs3213245 polymorphism was correlated with the overall survival in OS patients.\
**Abbreviations:** OS, osteosarcoma; XRCC1, X-ray repair cross-complementing group-1.](cmar-10-4959Fig1){#f1-cmar-10-4959}

![Effect of rs3213245 polymorphism in the XRCC1 transcriptional activity.\
**Notes:** Schematic representation of reporter plasmids containing T or C allele at rs3213245, which was inserted into upstream of the luciferase reporter gene in the pGL3 plasmid. pRL-SV40 were cotransfected into SaOS2, MG-63 cells as the internal control of Renilla luciferase. Columns, mean from three independent experiments; bars, SD.\
**Abbreviation:** XRCC1, X-ray repair cross-complementing group-1.](cmar-10-4959Fig2){#f2-cmar-10-4959}

![Effect of rs3213245 polymorphism on XRCC1 expression in OS patients.\
**Notes:** (A) XRCC1 mRNA expression in OS tumor tissues was detected by qRT-PCR. (B) XRCC1 protein levels were evaluated by Western blotting; OS patients with TT genotype (n=6); OS patients with CC genotype (n=3); OS patients with TC genotype (n=3).\
**Abbreviations:** OS, osteosarcoma; qRT-PCR; quantitative real-time PCR; XRCC1, X-ray repair cross-complementing group-1.](cmar-10-4959Fig3){#f3-cmar-10-4959}

###### 

The characteristics of OS patients and normal controls

  Characteristics                OS cases (n=146)   Normal controls (n=248)   *P*-value
  ------------------------------ ------------------ ------------------------- -----------
                                                                              
  **Age (years)**                                                             
  \<20                           85                 147                       0.92
  \>20                           61                 101                       
  **Gender (n, %)**                                                           
  Male                           86                 159                       0.33
  Female                         60                 89                        
  **Tumor location**                                                          
  Femur                          83                                           
  Tibia                          42                                           
  Other                          21                                           
  **Tumor size (cm)**                                                         
  \<6                            76                                           
  \>6                            70                                           
  **Tumor grade**                                                             
  Low                            71                                           
  High                           75                                           
  **Clinical stage**                                                          
  IIA                            46                                           
  IIB                            73                                           
  III                            27                                           
  **Distant metastasis**                                                      
  Negative                       100                                          
  Positive                       46                                           
  **Response to chemotherapy**                                                
  Poor                           81                                           
  Good                           65                                           

**Abbreviation:** OS, osteosarcoma.

###### 

Genotype frequencies of XRCC1 polymorphisms among OS patients and normal controls

  SNP         Genotype/allele   OS (n, %)       Controls (n, %)   HWE    OR (95% CI)             *P*-value
  ----------- ----------------- --------------- ----------------- ------ ----------------------- -----------
                                                                                                 
  rs3213245   TT                103 (70.5)      202 (81.5)        0.36   Reference               
              **TC**            **40 (27.4)**   **45 (18.1)**            **1.74 (1.07--2.84)**   **0.03**
              CC                3 (2.1)         1 (0.4)                  5.88 (0.60--57.5)       0.13
              **TC + CC**       **43 (29.5)**   **46 (18.5)**            **1.83 (1.14--3.00)**   **0.02**
              T                 246 (84.2)      449 (90.5)               Reference               
              **C**             **46 (15.8)**   **47 (9.5)**             **1.79 (1.16--2.76)**   **0.01**
  rs1799782   CC                76 (52.1)       130 (52.4)        0.84   Reference               
              CT                60 (41.1)       100 (40.3)               1.03 (0.67--1.57)       0.91
              TT                10 (6.8)        18 (7.3)                 0.95 (0.42--2.17)       1.00
              CT + TT           70 (47.9)       118 (47.6)               1.02 (0.67--1.53)       0.94
              C                 212 (72.6)      360 (72.6)               Reference               
              T                 80 (27.4)       136 (27.4)               1.00 (0.72--1.38)       0.90
  rs25489     GG                119 (81.5)      208 (83.9)        0.85   Reference               
              GA                26 (17.8)       38 (15.3)                1.20 (0.69--2.07)       0.57
              AA                1 (0.7)         2 (0.8)                  0.87 (0.08--9.74)       0.91
              GA + AA           27 (18.5)       40 (16.1)                1.18 (0.69--2.02)       0.58
              G                 264 (90.4)      454 (91.5)               Reference               
              A                 28 (9.6)        42 (8.5)                 1.15 (0.69--1.89)       0.61
  rs25487     GG                83 (56.8)       126 (50.8)        0.66   Reference               
              GA                53 (36.3)       103 (41.5)               0.78 (0.51--1.20)       0.28
              AA                10 (6.9)        24 (9.7)                 0.63 (0.29--1.39)       0.34
              GA + AA           63 (43.2)       127 (51.2)               0.75 (0.50--1.14)       0.18
              G                 219 (75.0)      355 (71.6)               Reference               
              A                 73 (25.0)       151 (30.4)               0.78 (0.57--1.08)       0.16

**Note:** Statistically significant genotypes/alleles and values are shown in bold.

**Abbreviations:** HWE, Hardy Weinberg Equilibrium; OS, osteosarcoma; SNP, single-nucleotide polymorphism; XRCC1, X-ray repair cross-complementing group-1.

###### 

The association of rs3213245 with clinicopathologic characteristics in OS patients

  Characteristic                 Patients (N)   Genotypes   Allele                                                  
  ------------------------------ -------------- ----------- ----------------------- ------------------- ----------- -----------------------
                                                                                                                    
  **Age (years)**                                                                                                   
  \<20                           85             59          25                      1                   143         27
  \>20                           61             44          15                      2                   103         19
  OR (95% CI)                                   Reference   0.81 (0.38--1.70)       2.68 (0.24--30.5)   Reference   0.98 (0.52--1.85)
  *P*-value                                     --          0.71                    0.58                --          0.94
  **Gender (n, %)**                                                                                                 
  Male                           86             65          20                      1                   150         22
  Female                         60             38          20                      2                   96          24
  OR (95% CI)                                   Reference   1.71 (0.82--3.58)       3.42 (0.30--39.0)   Reference   1.71 (0.91--3.21)
  *P*-value                                     --          0.19                    0.56                --          0.11
  **Tumor location**                                                                                                
  Femur/Tibia/Fibula             125            82          30                      3                   194         36
  Other                          21             11          10                      0                   32          10
  OR (95% CI)                                   Reference   2.49 (0.96--6.45)       --                  Reference   1.68 (0.76--3.73)
  *P*-value                                     --          0.07                    --                  --          0.26
  **Tumor size (cm)**                                                                                               
  \<6                            71             56          14                      1                   126         16
  \>6                            75             47          26                      2                   120         30
  OR (95% CI)                                   Reference   **2.21 (1.04--4.72)**   2.38 (0.21--27.1)   Reference   1.97 (1.02--3.80)
  *P*-value                                     --          0.35                    0.60                --          0.06
  **Pathological grade**                                                                                            
  High differentiation           76             57          18                      1                   132         20
  Low differentiation            70             46          22                      2                   114         26
  OR (95% CI)                                   Reference   1.51 (0.73--3.16)       2.48 (0.22--28.1)   Reference   1.51 (0.80--2.84)
  *P*-value                                     --          0.35                    0.59                --          0.26
  **Metastasis at diagnosis**                                                                                       
  Negative                       100            78          22                      0                   178         22
  Positive                       46             25          18                      3                   68          24
  OR (95% CI)                                   Reference   **2.55 (1.18--5.51)**   --                  Reference   **2.86 (1.50--5.43)**
  *P*-value                                     --          0.02                    0.01                --          \<0.01
  **Response to chemotherapy**                                                                                      
  Poor                           81             61          20                      0                   142         20
  Good                           65             42          20                      3                   104         26
  OR (95% CI)                                   Reference   1.45 (0.70--3.03)       --                  Reference   1.78 (0.94--3.35)
  *P*-value                                     --          0.35                    --                  --          0.09

**Note:** Statistically significant values are shown in bold.

**Abbreviations:** --, not applicable; OS, osteosarcoma.

###### 

Univariate and multivariate Cox proportional hazard analyses for OS patients' overall survival

  Factor                  Category              Univariate              Multivariate
  ----------------------- --------------------- ----------------------- -----------------------
                                                                        
  Age (years)             ≥20/\<20              1.15 (0.67--2.06)       
  Gender                  Male/female           1.41 (0.80--2.97)       
  Tumor location          Femur + tibia/other   0.91 (0.57--2.03)       
  Tumor size              ≥6/\<6 cm             2.05 (0.93--2.78)       
  Tumor grade             Poor/good             **2.11 (1.65--3.77)**   1.83 (0.66--3.21)
  Distant metastases      Yes/no                **4.59 (3.66--6.28)**   **4.01 (2.34--6.09)**
  Chemotherapy response   Poor/good             **3.70 (2.51--6.08)**   **2.32 (1.67--4.57)**
  rs3213245               TC + CC/TT            **1.89 (1.16--3.07)**   1.41 (0.86--2.62)

**Note:** Statistically significant values are shown in bold.

**Abbreviation:** OS, osteosarcoma.
